Assembly Biosciences
Seema Kishore has extensive work experience in the field of accounting and finance. Seema currently holds the position of Senior Accountant at Assembly Biosciences, Inc., where they have been working since February 2020. Prior to this, they also served as a Senior Accountant at the same company.
Before joining Assembly Biosciences, Inc., Seema worked as a Senior Accounts Payable Accountant at Guardant Health from July 2017 to October 2019. Seema also held the position of Accounts Payable Specialist at Sitecore from September 2016 to February 2017.
In addition, Seema worked as a Senior Accounts Payable Specialist at Pro Unlimited @ Facebook from March 2016 to June 2016, and as a Senior Accounts Payable Analyst at Amobee from March 2015 to March 2016.
Their earliest work experience in the industry was as a Procure to Pay Analyst at Gilead Sciences, where they worked from September 2007 to March 2015.
Overall, Seema Kishore has a strong background in accounting and finance, with a focus on accounts payable and procurement.
Seema Kishore's education history includes attending Notre Dame de Namur University from 2013 to 2016, where they received a Bachelor of Science (BS) degree in Business Administration and Management, with a focus on General studies. Prior to that, they attended San Mateo High School from 1992 to 1995. No specific degree or field of study is mentioned for their high school education.
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.